In the investigated cohort of patients with ND-CKD who had stable Hb levels of 11–12 g/dL but were iron-deficient despite oral iron treatment for at least six months, a switch from oral iron to i.v. FCM significantly reduced ESA dose requirements, increased Hb levels and improved iron status. This evidence concerns the gene GSTM1 and chronic kidney disease.